Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study

BACKGROUND: In the EMPA-REG OUTCOME trial (Empagliflozin Cardiovascular Outcome Event Trial) treatment with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin significantly reduced heart failure hospitalization (HHF) in patients with type 2 diabetes mellitus (T2D) and established car...

Descripción completa

Detalles Bibliográficos
Autores principales: Rau, Matthias, Thiele, Kirsten, Hartmann, Niels-Ulrik Korbinian, Schuh, Alexander, Altiok, Ertunc, Möllmann, Julia, Keszei, András P., Böhm, Michael, Marx, Nikolaus, Lehrke, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791833/
https://www.ncbi.nlm.nih.gov/pubmed/33413355
http://dx.doi.org/10.1186/s12933-020-01175-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7791833/
https://www.ncbi.nlm.nih.gov/pubmed/33413355
http://dx.doi.org/10.1186/s12933-020-01175-5

Ejemplares similares